Acasti pharma reports topline results for trilogy 1 phase 3 trial of capre

Acasti pharma reports topline results for trilogy 1 phase 3 trial of capre.acasti pharma - reports 30.5%, 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving capre at 12, 26 weeks respectively.acasti pharma inc - no treatment-related serious adverse events reported in trial.acasti pharma inc - reports 42.2% reduction in triglyceride levels among patients receiving capre while on background statin therapy at 12 weeks.acasti pharma inc - study did not reach statistical significancedue to unusually large placebo effect; further analysis is underway.acasti pharma inc - topline results for trilogy 2 trial expected now by mid-february 2020.acasti pharma inc - results for all of secondary and exploratory endpoints in capre trial expected to be available by end of q1, 2020.acasti pharma - given cornstarch is likely not root cause for significant placebo response in trilogy 1, co is evaluating other possible explanations.acasti pharma inc - implementation of trilogy 2 study remains on track.acasti pharma inc - there could be a small delay of a couple weeks in reporting topline results for trilogy 2 to mid-feb 2020.acasti pharma inc - a high placebo response at 5 sites disproportionately contributed to overall placebo response in capre trial.
ACST Ratings Summary
ACST Quant Ranking